REG - ConvaTec Group PLC - Block Listing Application

ConvaTecAnnouncement

20/12/2021 08:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211220:nRST1759Wa&default-theme=true

RNS Number : 1759W  ConvaTec Group PLC  20 December 2021

ConvaTec Group Plc

 

Block Listing Application

 

 

Reading, United Kingdom - 20 December 2021

 

 

An application has been made to the Financial Conduct Authority and the London
Stock Exchange for a block listing totalling 20,000,000 ordinary shares of 10
pence each ("Shares") to be admitted to the premium listing segment of the
Official List of the FCA and to trading on the London Stock Exchange's main
market for listed securities. When issued these Shares will rank pari passu
with the existing ordinary shares.

 

 

These Shares are being reserved under a block listing and will be issued from
time to time pursuant to the following scheme(s):

 

 Scheme                                              Number of Shares
 ConvaTec Group Plc Long Term Incentive Plan         9,850,000
 ConvaTec Group Plc US Employee Stock Purchase Plan  290,000
 ConvaTec Group Plc Share Plan                       3,000,000
 ConvaTec Group Plc Deferred Bonus Plan              430,000
 ConvaTec Group Plc UK SAYE                          1,830,000
 ConvaTec Group Plc Global SAYE Sub-Plan             4,600,000

 

Admission of the Shares is expected on 21 December 2021.

 

Enquiries

Analysts and Investors

Kate Postans, VP Investor Relations, ConvaTec
      +44 (0)782 644 7807

ir@convatec.com (mailto:ir@convatec.com)

 

Media

Buchanan: Chris Lane
 
+44 (0)207 466 5000
 
 

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

About ConvaTec

ConvaTec is a global medical products and technologies company focused on
therapies for the management of chronic conditions, with leading market
positions in advanced wound care, ostomy care, continence and critical care,
and infusion care. Our vision, which encompasses our purpose, is: Pioneering
trusted medical solutions to improve the lives we touch. Our products provide
a range of clinical and economic benefits including infection prevention,
protection of at-risk skin, improved patient outcomes and reduced total cost
of care. To learn more about ConvaTec, please visit www.convatecgroup.com
(http://www.convatecgroup.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSFEASWSEFSELE